PH12022552366A1 - Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof - Google Patents

Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof

Info

Publication number
PH12022552366A1
PH12022552366A1 PH1/2022/552366A PH12022552366A PH12022552366A1 PH 12022552366 A1 PH12022552366 A1 PH 12022552366A1 PH 12022552366 A PH12022552366 A PH 12022552366A PH 12022552366 A1 PH12022552366 A1 PH 12022552366A1
Authority
PH
Philippines
Prior art keywords
chloro
bis
salts
amino
methoxybenzo
Prior art date
Application number
PH1/2022/552366A
Other languages
English (en)
Inventor
Axel Becker
Delia-Maria Gruia
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PH12022552366A1 publication Critical patent/PH12022552366A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH1/2022/552366A 2020-04-17 2021-04-14 Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof PH12022552366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20170197 2020-04-17
PCT/EP2021/059604 WO2021209477A1 (en) 2020-04-17 2021-04-14 Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof

Publications (1)

Publication Number Publication Date
PH12022552366A1 true PH12022552366A1 (en) 2024-03-18

Family

ID=70333787

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/552366A PH12022552366A1 (en) 2020-04-17 2021-04-14 Crystalline forms of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol and salts thereof

Country Status (8)

Country Link
US (1) US20230295156A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136087A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023522023A (cg-RX-API-DMAC7.html)
CN (1) CN115515955A (cg-RX-API-DMAC7.html)
BR (1) BR112022018436A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175552A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552366A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021209477A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100975895B1 (ko) * 2008-04-29 2010-08-18 강민석 피로나리딘의 제조방법 및 이를 위한 중간체
CN101544638B (zh) * 2009-05-12 2012-05-30 重庆通天药业有限公司 乳酸咯萘啶及其药物组合物
CN103373995B (zh) * 2012-04-28 2016-04-27 上海迪赛诺药业有限公司 一种制备咯萘啶的方法
US9994577B2 (en) * 2014-07-04 2018-06-12 Merck Patent Gmbh Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
CN105461713A (zh) * 2014-09-25 2016-04-06 刘力 苯并萘啶类的新化合物及其组合物和用途
BR112019006456A2 (pt) * 2016-10-13 2019-06-25 Medicines For Malaria Venture Mmv diespiro 1,2,4-trioxolano, formulação farmacêutica, processo para a preparação de um derivado de diespiro 1,2,4-trioxolano, intermediário, e, método para prevenir e/ou tratar malária e esquistossomose ou um câncer.
MX2020009711A (es) * 2018-04-11 2020-10-07 Merck Patent Gmbh Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos.
CN112209926A (zh) * 2019-07-12 2021-01-12 中国中医科学院中药研究所 磷酸咯萘啶的多晶型物及其制备方法、应用
CN116507331A (zh) * 2020-06-15 2023-07-28 默克专利有限公司 Tlr7/8拮抗剂及其用途

Also Published As

Publication number Publication date
CN115515955A (zh) 2022-12-23
BR112022018436A2 (pt) 2022-11-01
WO2021209477A1 (en) 2021-10-21
US20230295156A1 (en) 2023-09-21
EP4136087A1 (en) 2023-02-22
JP2023522023A (ja) 2023-05-26
CA3175552A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
ZA202301437B (en) Compounds and methods for treatment of viral infections
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
PH12022553530A1 (en) 1'-cyano nucleoside analogs and uses thereof
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
AR111490A1 (es) Formas cristalinas de propanoato de (s)-2-etilbutil 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)
HRP20050821A2 (en) Hiv replication inhibiting pyrimidines and triazines
BR0307267A (pt) Compostos heterocìclicos, ativos como inibidores de beta-lacta-mases
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
BR112012024691A2 (pt) composto, e, composição farmacêutica
EP4480483A3 (en) Solid state forms of belumosudil and belumosudil salts
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
BR0203274A (pt) teres aromáticos de difluorometilenos
BR0212069A (pt) Agentes antidiabéticos orais
MX2020007521A (es) Inhibidores de pi4kiii.
DOP2025000019A (es) Inhibidores de la proteasa principal de sars-cov2
MX2025014096A (es) Compuesto espirociclico de oxoisoindolinil piperidina-2,6-diona sustituida
MX390374B (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
MX382439B (es) Compuestos de carbapenem
CA2455621A1 (en) Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
BR112018075823A2 (pt) sais farmacêuticos de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida e suas formas cristalinas